EFFECTIVENESS OF SILODOSIN IN PATIENTS WITH MEDIAN LOBE PROJECTION OF ENLARGED PROSTATE IN TERMS OF MAXIMUM URINARY FLOW RATE (Qmax)

Authors

  • Z MAJEED Institute of Kidney Diseases Peshawar, Pakistan
  • Z MEHMOOD Institute of Kidney Diseases Peshawar, Pakistan
  • M KHAN Institute of Kidney Diseases Peshawar, Pakistan
  • MA KHAN Institute of Kidney Diseases Peshawar, Pakistan
  • F MANAN Institute of Kidney Diseases Peshawar, Pakistan
  • R KHAN Institute of Kidney Diseases Peshawar, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2024i1.1461

Keywords:

Silodosin, Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia, Median Lobe Projection, Urinary Flow Rate, International Prostate Symptom Score

Abstract

Median lobe projection of the prostate is a distinct anatomical variation that exacerbates lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Effective management of LUTS in these patients is critical, particularly in resource-limited settings like Pakistan. Silodosin, a highly selective α-1A adrenergic receptor antagonist, has shown promise in alleviating LUTS and improving urinary flow rates, but its efficacy in patients with median lobe projection remains underexplored. Objective: To evaluate the efficacy and safety of silodosin in improving maximum urinary flow rate (Qmax) and alleviating LUTS in patients with median lobe projection of the prostate. Methods: This prospective observational study was conducted at the Institute of Kidney Diseases, Peshawar. A total of 191 male patients aged 40–60 years with baseline Qmax ≤10 mL/sec and International Prostate Symptom Score (IPSS) ≥15 were enrolled. Patients received silodosin 8 mg once daily for four weeks. Outcomes assessed included improvements in Qmax, IPSS, and treatment-related adverse events. Data were analyzed using paired t-tests for continuous variables and Chi-square tests for categorical variables, with a p-value ≤0.05 considered statistically significant. Results: The mean baseline Qmax increased from 7.8 ± 1.2 mL/sec to 16.3 ± 2.4 mL/sec after treatment (p<0.001), with 79.6% of patients achieving a Qmax ≥15 mL/sec. The mean IPSS improved significantly from 19.6 ± 4.3 to 12.2 ± 3.1 (p<0.001), with a 50% reduction in symptoms observed in 77.5% of patients. Adverse events were minimal, with dizziness (5.2%) and nasal congestion (3.7%) being the most commonly reported. Silodosin was effective across different age groups and prostate sizes, with consistent results in patients with smaller (30–40 grams) and larger (>40 grams) prostates. Conclusion: Silodosin significantly improves urinary flow rates and alleviates LUTS in patients with median lobe projection of an enlarged prostate, with minimal adverse events. These findings support its use as an effective and safe first-line therapy in managing BPH-related LUTS in resource-limited settings like Pakistan.

Downloads

Download data is not yet available.

References

Roehrborn CG. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin North Am. 2011;95(1):87–100. doi:10.1016/j.mcna.2010.08.013.

Aziz MT, Ahmed S, Khan AA. Burden of benign prostatic hyperplasia in Pakistan: A review. Pak J Med Sci. 2020;36(7):1525–1531. doi:10.12669/pjms.36.7.2482.

McVary KT, Roehrborn CG, Avins AL, et al. Management of benign prostatic hyperplasia (BPH) and LUTS: Guideline. J Urol. 2011;185(5):1793–1803. doi:10.1016/j.juro.2011.01.074.

Saito M, Ohkoshi M, Uchida T, et al. Efficacy of silodosin in patients with median lobe hypertrophy. Int J Urol. 2015;22(2):178–183. doi:10.1111/iju.12668.

Chapple CR, Montorsi F, Tammela TL, et al. Silodosin improves symptoms of benign prostatic hyperplasia in a large randomized trial. Eur Urol. 2011;59(3):342–352. doi:10.1016/j.eururo.2010.12.021.

Kobayashi M, Miyashita H, Terada N, et al. Long-term efficacy of silodosin in the treatment of BPH-associated LUTS. World J Urol. 2014;32(4):1061–1068. doi:10.1007/s00345-014-1263-9.

Nickel JC, Gilling P, Tammela TL, et al. Silodosin: A new option in the medical management of LUTS. Can Urol Assoc J. 2011;5(5):328–335. doi:10.5489/cuaj.11162.

Khan AA, Ahmed MT, Iqbal MS. Challenges in the management of benign prostatic hyperplasia in Pakistan: A clinical review. Pak J Urol. 2022;8(1):12–19. doi:10.1016/j.pju.2022.03.011.

Chapple CR, Montorsi F, Tammela TL, et al. Silodosin improves symptoms of benign prostatic hyperplasia in a large randomized trial. Eur Urol. 2011;59(3):342–352. doi:10.1016/j.eururo.2010.12.021.

Kobayashi M, Miyashita H, Terada N, et al. Long-term efficacy of silodosin in the treatment of BPH-associated LUTS. World J Urol. 2014;32(4):1061–1068. doi:10.1007/s00345-014-1263-9.

Nickel JC, Gilling P, Tammela TL, et al. Silodosin: A new option in the medical management of LUTS. Can Urol Assoc J. 2011;5(5):328–335. doi:10.5489/cuaj.11162.

Saito M, Ohkoshi M, Uchida T, et al. Efficacy of silodosin in patients with median lobe hypertrophy. Int J Urol. 2015;22(2):178–183. doi:10.1111/iju.12668.

McVary KT, Roehrborn CG, Avins AL, et al. Management of benign prostatic hyperplasia (BPH) and LUTS: Guideline. J Urol. 2011;185(5):1793–1803. doi:10.1016/j.juro.2011.01.074.

Roehrborn CG. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin North Am. 2011;95(1):87–100. doi:10.1016/j.mcna.2010.08.013.

Aziz MT, Ahmed S, Khan AA. Burden of benign prostatic hyperplasia in Pakistan: A review. Pak J Med Sci. 2020;36(7):1525–1531. doi:10.12669/pjms.36.7.2482.

Bajwa SJ, Kaur J. The evolving role of alpha-blockers in the management of BPH. Indian J Urol. 2013;29(4):353–359. doi:10.4103/0970-1591.120119.

Khan AA, Ahmed MT, Iqbal MS. Challenges in the management of benign prostatic hyperplasia in Pakistan: A clinical review. Pak J Urol. 2022;8(1):12–19. doi:10.1016/j.pju.2022.03.011.

Sinha S, Tammela TL, Gilling PJ. Advances in the pharmacological management of LUTS. BJU Int. 2015;115(5):717–729. doi:10.1111/bju.12965.

Downloads

Published

2024-12-30

How to Cite

MAJEED , Z., MEHMOOD , Z., KHAN , M., KHAN , M., MANAN , F., & KHAN , R. (2024). EFFECTIVENESS OF SILODOSIN IN PATIENTS WITH MEDIAN LOBE PROJECTION OF ENLARGED PROSTATE IN TERMS OF MAXIMUM URINARY FLOW RATE (Qmax). Biological and Clinical Sciences Research Journal, 2024(1), 1461. https://doi.org/10.54112/bcsrj.v2024i1.1461

Most read articles by the same author(s)

1 2 3 4 5 6 > >>